In a report released yesterday, Balaji Prasad from Barclays maintained a Buy rating on Elanco Animal Health (ELAN – Research Report), with a price target of $18.00. The company’s shares closed yesterday at $16.16.
Prasad covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, Coherus Biosciences, and Idexx Laboratories. According to TipRanks, Prasad has an average return of 3.2% and a 46.95% success rate on recommended stocks.
Elanco Animal Health has an analyst consensus of Moderate Buy, with a price target consensus of $17.07, which is a 5.63% upside from current levels. In a report released on February 6, Bank of America Securities also maintained a Buy rating on the stock with a $18.00 price target.
See the top stocks recommended by analysts >>
Based on Elanco Animal Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.07 billion and a GAAP net loss of $1.1 billion. In comparison, last year the company earned a revenue of $1.03 billion and had a GAAP net loss of $65 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Elanco Animal Health (ELAN) Company Description:
Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.
Read More on ELAN:
